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ABSTRACT
Receptor-binding affinity and ligand-receptor residence time
are key parameters for the selection of drug candidates and are
routinely determined using radioligand competition-binding assays.
Recently, a novel bioluminescence resonance energy transfer
(BRET) method utilizing a NanoLuc-fused receptor was in-
troduced to detect fluorescent ligand binding. Moreover, this
NanoBRET method gives the opportunity to follow fluorescent
ligand binding on intact cells in real time, and therefore, results
might better reflect in vivo conditions as compared with the
routinely used cell homogenates or purified membrane fractions.
In this study, a real-time NanoBRET-based binding assay was
established and validated to detect binding of unlabeled ligands
to the histamine H3 receptor (H3R) and histamine H4 receptor on
intact cells. Obtained residence times of clinically tested H3R
antagonists were reflected by their duration of H3R antagonism
in a functional receptor recovery assay.
Introduction
Blockbuster antihistamines targeting the histamine H1 and
H2 receptors have been used for many decades to alleviate
allergy symptoms and gastric acid–related disorders, respec-
tively (Panula et al., 2015). In contrast, drug discovery pro-
grams on the other two members of the histamine receptor
family are still ongoing. The histamine H3 receptor (H3R) is
predominantly expressed in the central nervous system and
considered a therapeutic target for neurologic disorders, such as
Alzheimer’s and Parkinson’s diseases, attention deficit hyperac-
tivity disorder, epilepsy, and narcolepsy (Wijtmans et al., 2007;
Sadek et al., 2016). The histamine H4 receptor (H4R) is pre-
dominantly expressed on immune cells and linked to inflamma-
tory disorders, such as psoriasis, atopic dermatitis, asthma, and
arthritis (Novak et al., 2012; Verweij et al., 2017). In 2016, the
first H3R-targeting therapeutic, pitolisant (Wakix, Bioprojet
Pharma,Paris, France),was approvedby theEuropeanMedicine
Agency for the treatment of narcolepsy (Kollb-Sielecka et al.,
2017), whereas H4R-targeting drug candidates are in clinical
trials for the treatment of various inflammatory disorders
(Thurmond, 2015; Attali et al., 2016; Thurmond et al., 2017).
Traditionally, radioligands are used in competition binding
experiments to indirectly determine the binding affinities (Ki),
association (kon), and dissociation (koff) rate constants of the
binding of unlabeled ligands to a receptor. However, these
radioligand-based methods generally require physical sepa-
ration of free and bound radioligands to quantify receptor-
bound radioligand. Consequently, these endpoint assays are
particularly labor intensive, as each measured time point
requires a separate binding reaction. Recently, a novel proximity-
based method was introduced for the histamine H1 receptor and
a number of other G protein–coupled receptors (GPCRs) by
genetic fusion of an engineered enzyme, NanoLuc (Nluc), to
the N-terminus of these receptors, allowing only the detection
of bound fluorescent ligand via bioluminescence resonance
energy transfer (nanoBRET). Consequently, this novel method
does not require physical separation of free from bound fluores-
cent ligand (Stoddart et al., 2015; Soave et al., 2016). Hence, this
proximity-based (,10 nm) method allows real-time measure-
ment of ligand binding to GPCRs on intact cells. Moreover, no
additional prelabeling steps are required in contrast to the
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time-resolved fluorescence resonance energy transfer–based
Tag-lite ligand-receptor-binding assay,which uses Tb31-cryptate
conjugated to an N-terminal SNAP-tagged receptor as a reso-
nance energy transfer donor (Zwier et al., 2010; Sykes et al.,
2017). The development and commercial availability of fluores-
cent H3R and H4R ligands urged us to set up and validate a
NanoBRET-based binding assay for the H3R and H4R (Tomasch
et al., 2012; Vernall et al., 2014; Mirzahosseini et al., 2015). In
this study, a NanoBRET-based binding assay was established
and validated to detect binding of unlabeled ligands to the
human H3R (hH3R) and human H4R (hH4R) on intact cells.
Materials and Methods
Materials. Na-[methyl-3H]histamine ([3H]NAMH) (specific activity
79.7 Ci/mmol), [3H]histamine (specific activity 10.6 Ci/mmol),
Microscint-O scintillation liquid, and GF/C filter plates were pur-
chased from PerkinElmer (Groningen, The Netherlands). Clobenpro-
pit-BODIPY-630/650 (clo-BDY, CA200843) was purchased from Hello
Bio (Bristol, UK), and BODIPY-FL-histamine (FL-histamine) was pur-
chased fromSetarehBiotech (Eugene,OR).Thioperamideandclobenpropit
were purchased from Abcam (Cambridge, UK), Trans-N-Ethyl-3-fluoro-
3-[3-fluoro-4-(1-pyrrolidinylmethyl)phenyl]-cyclobutanecarboxamide 4-
methylbenzenesulfonate (PF-03654746)and4-(2-{2-[(2R)-2-Methylpyrrolidin-
1-yl]ethyl}-benzofuran-5-yl)benzonitrile (ABT-239) were obtained from
AxonMedchem (Groningen, TheNetherlands), andS-a-methylhistamine
(SAMH) andNa-methylhistamine (NAMH) were obtained from Tocris
(Abingdon, UK). Pitolisant and (4-Cyclopropyl-piperazin-1-yl)-(4-
morpholin-4-ylmethyl-phenyl)-methanone bavisant (JNJ31001074) were
obtained from Griffin Discoveries (Amsterdam, The Netherlands).
A-331440 [(49-[3-(3(R)-(dimethylamino)-pyrrolidin-1-yl)-propoxy]-biphenyl-
4-carbonitrile] was synthesized at the Department of Radiology and
NuclearMedicine, VUUniversityMedical CenterAmsterdam (Amsterdam,
The Netherlands) and is commercially available at Tocris. GSK1004723
(4-[(4-Chlorophenyl)methyl]-2-({(2R)-1-[4-(4-{[3-(hexahydro-1H-azepin-
1-yl)propyl]oxy}phenyl)butyl]-2-pyrrolidinyl}methyl)-1(2H)-phthalazinone)
was a kind gift fromDr. Slack fromGlaxoSmithKline (Stevenage, UK)
(Slack et al., 2011). GSK189254 (6-[(3-cyclobutyl-2,3,4,5-tetrahydro-
1H-3-benzazepin-7-yl)oxy]-N-methylpyridine-3-carboxamide) was
purchased fromAdvancedChemBlocks Inc. (Burlingame, CA). All other
ligandswere synthesized in house as previously described (van der Goot
et al., 1992; Jansen et al., 1994; Vollinga et al., 1994, 1995; De Esch
et al., 1999; Jablonowski et al., 2003; Lim et al., 2006, 2009; Smits et al.,
2008). NanoGlowas obtained fromPromega (Madison,WI). Fetal bovine
serum was obtained from Bodinco (Alkmaar, The Netherlands), and
penicillin/streptomycin was purchased from GE Healthcare (Uppsala,
Sweden). Hanks’ balanced salt solution (HBSS) was obtained fromGibco
(Thermo Fisher Scientific, Waltham, MA). The cAMP-responsive ele-
ment (CRE)–driven luciferase reporter gene plasmid pTLNC-21CRE
was kindly provided byDr. Born (National JewishMedical andResearch
Center, Denver, CO), whereas the BRET-based cAMP biosensor plasmid
pcDNA3.1-(L)-His-CAMYEL (cAMP sensor using YFP-Epac-RLuc,
#ATCC-MBA-277) was purchased from the American Type Culture
Collection (Manassas, VA). All other chemicals were bought from
standard commercial resources and were of analytical grade.
Cloning of Nluc-hH3R and Nluc-hH4R Fusion Constructs.
The start codons of the human H3R and H4R [Genbank: AF140538
(Lovenberg et al., 1999) and AY136745, respectively] were substituted
with a Kpn2I restriction site sequence using polymerase chain reaction.
The cDNA plasmid encoding the membrane signal peptide of the
5HT3A receptor fused to Nluc was a gift from Dr. Hill (University of
Nottingham, Nottingham, UK) (Stoddart et al., 2018b). Flanking
KpnI and Kpn2I restriction sites were introduced at the 59 and 39 end
of this signal peptide–Nluc cDNA by polymerase chain reaction,
allowing in-frame fusion to the N terminus of hH3R (Lovenberg
et al., 1999) and hH4R in the pcDEF3 mammalian expression vector
(Goldman et al., 1996). All generated constructs were validated by
sequencing (Eurofins Genomics, Ebersberg, Germany).
Cell Culture and Transfection. Human embryonic kidney
293T cells (HEK293T cells) were cultured in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal bovine serum, penicillin
(100 mg/ml), and streptomycin (50 mg/ml) at 37°C with 5% CO2.
HEK293T cells were seeded (2 106 cells/10 cm2 dish) and transiently
transfected the next day with indicated amounts of cDNA using
25 kDa linear polyethyleneimine (PEI). The total amount of cDNAwas
kept constant at 5 mg per dish by the addition of complementary
amounts of pcDEF3 plasmid. DNA/PEI (1:4 ratio) mixtures were
preincubated in 150 mM NaCl solution for 20 minutes at 22°C before
addition to the cells (Nijmeijer et al., 2013a).
Radioligand-Binding Assays. HEK293T cells were transfected
with 2.5 mg of DNA encoding for wild-type and Nluc-fused hH3R or
hH4R. After 48 hours, cells were collected in phosphate-buffered saline
(PBS) and centrifuged at 1900g for 10 minutes. The cell pellet was
resuspended in 1 ml of PBS per culture dish and centrifuged at 1900g
for 10 minutes. Supernatant was discarded and the cell pellet was
stored at220°C until the day of the experiment. Cells were resuspended
in binding buffer (50 mM Tris-HCl, pH 7.4, 22°C) and disrupted using a
Branson sonifier 250 (Boom bv., Meppel, The Netherlands) on the day of
the experiment.
Saturation radioligand binding was performed on 100 ml of cell
homogenates expressing the hH3R, Nluc-hH3R, hH4R, or Nluc-hH4R
with increasing concentrations of [3H]NAMH or [3H]histamine for
2 hours at 25°C. Nonspecific binding was measured in the presence of
100 mM clobenpropit or 10 mM JNJ7777120 (1-[(5-chloro-1H-indol-2-
yl)carbonyl]-4-methylpiperazine). Equilibrium competition binding
was performed on 100 ml of cell homogenates expressing the hH3R
with ∼2 nM [3H]NAMH or expressing the hH4R with ∼10 nM
[3H]histamine in the absence and presence of increasing concentra-
tions of unlabeled ligands for 2 hours at 25°C. Incubations were
terminated by rapid filtration over a 0.5% PEI-coated 96-well GF/C
filter plate followed by five rapid wash steps with ice-cold wash
buffer (50 mM Tris-HCl, pH 7.4, 4°C) using a PerkinElmer 96-well
Filtermate-harvester. The GF/C filter plates were dried at 55°C, and
25 ml of Microscint-O scintillation liquid (PerkinElmer, Groningen,
The Netherlands) was added per well. Filter-bound radioactivity was
measured using a Microbeta Wallac Trilux scintillation counter
(PerkinElmer) after a 300-minute delay.
NanoBRET-Based Binding Assays. HEK293T cells were trans-
fected with cDNA encoding 0.5 mg of Nluc-hH3R or Nluc-hH4R. The
next day, cells were transferred to poly-L-lysine–coated black 96-well
plates (50,000 cells/well) and grown for anadditional 24hours.Equilibrium
saturation binding of fluorescent clo-BDY or FL-histamine to intact cells
expressing Nluc-hH3R and Nluc-hH4R was measured in a total volume of
100ml of HBSS for 2 hours at 25°C.Nonspecific bindingwas determined
by 100mMclobenpropit or 10mMJNJ7777120 for Nluc-hH3R andNluc-
hH4R, respectively. To determine the affinity (pKi) of unlabeled ligands
for the Nluc-hH3R or Nluc-hH4R, the cells were incubated with 50 nM
clo-BDY or 1 mM FL-histamine in combination with increasing
concentrations of unlabeled ligands (ranging from 1025 to 10211 M)
in HBSS for 2 hours at 25°C. Binding of clo-BDY and FL-histamine
to the Nluc-hH3R or Nluc-hH4R was detected as a BRET ratio upon
the addition of 3.2 ml/ml NanoGlo (Promega, Madison, WI) using the
PHERAstar plate reader (BMGLabtech,Ortenberg, Germany) at 475 nm
(15-nmbandpass) and.610nm (longpass) for clo-BDYand460nm (80-nm
bandpass) and 535 nm (15-nm bandpass) for FL-histamine.
To measure clo-BDY-binding kinetics, Nluc-hH3R–expressing cells
were preincubated with 3.2 ml/ml NanoGlo (Promega) in HBSS for
15 minutes. Next, for association assays, 50, 100, or 200 nM clo-BDY
was added to the cells and nonspecific binding was measured in the
presence of 100 mM clobenpropit. For the competition association
assay, 100 nM clo-BDY was added in the absence and presence of
unlabeled ligands (10- or 40-fold Ki) in a total volume of 200 ml. In the
case of dissociation assays, cells were preincubated with 100 nM clo-
BDY for 2 hours before initiation of the dissociation by addition of














10 mM clobenpropit. Clo-BDY binding to the Nluc-hH3R was
directly measured every minute for 2 hours using a PHERAstar
plate reader (BMG) at 460 nm (80-nm bandpass) and .610 nm
(longpass).
CRE-Luciferase Reporter Gene Assay. HEK293T cells were
transiently transfected with 2.5 mg of CRE-luc DNA in combination
with 50 ng of Nluc-hH3R or 1000 ng of Nluc-hH4R, hH3R, or hH4R
DNA. The next day, cells were transferred to white poly-L-lysine–
coated 96-well plates (50,000 cells/well) and grown for an additional
24 hours. The cells were stimulated with increasing ligand concen-
trations in the absence or presence of a single concentration of
antagonist in Dulbecco’s modified Eagle’s medium supplemented
with 1 mM forskolin at 37°C and 5% CO2. The incubations were
terminated after 6 hours by replacing the medium with 25 ml/well
luciferase assay reagent [0.83 mMATP, 0.83 mM d-luciferin, 18.7 mM
MgCl2, 0.78 mM Na2PO4, 38.9 mM Tris-HCl (pH 7.8), 0.39% glycerol,
0.03% Triton-X-100, and 2.6 mM dithiothreitol]. Luminescence was
measured with a Mithras plate reader (Berthold, Bad Wildbad,
Germany) after 30 minutes at 37°C.
hH3R Functional Recovery Assay after Antagonist
Washout. HEK293T cells were transfected with 0.5 mg of hH3R
and 3 mg of CAMYEL DNA (Scholten et al., 2012). The next day,
cells were transferred to a poly-L-lysine–coated white 96-well
plate and preincubated overnight with 1 mM hH3R antagonist
pitolisant or ABT-239 at 37°C. Next, cells were washed twice with
PBS at different time points and allowed to re-equilibrate in HBSS
at 37°C. The cells were incubated with 5 mM coelenterazine-h and
40 mM 3-isobutyl-1-methylxanthine for 5 minutes, followed by a
stimulation with 1 mMhistamine. After 10 minutes, 1 mM forskolin
was added and luminescence was measured at 480 nm (20-nm
bandpass) (RLuc) and 540 nm (40-nm bandpass) (BRET) using the
Mithras multimode reader.
Data Analysis. Data were analyzed using GraphPad Prism 7.02
(GraphPad Software, SanDiego, CA). Data shown aremeans6 S.D. of
at least three independent experiments performed in triplicate, unless
stated differently. BRET ratio was calculated by dividing the fluorescent
acceptor signal by the signal of the luminescent donor. Competition-
binding curves were fitted to a one-sited bindingmodel to quantify the
IC50 value, and equilibrium dissociation constants (Ki) of unlabeled
ligands were subsequently calculated using the Cheng-Prusoff equa-





where [L] is the concentration of labeled ligand, and KD is the
equilibrium dissociation constant of the labeled ligand.
Association and dissociation data were fitted and subjected to an
extra-sum-of square F-test to compare between one- or two-phase
association and one- or two-phase exponential decay models. Compe-
tition association curves were fitted to Motulsky and Mahan model







KF 5 0:5ðKa 1Kb 1SÞ















where k1 and k3 (M
21×min21) are the association rate constants
(kon), whereas k2 and k4 (min
21) are the dissociation rate constants
(koff) of labeled and unlabeled ligand, respectively; [L] and [I] are the
concentrations of labeled and unlabeled ligand, respectively; Bmax is
the maximum specific binding sites; and Y is the specific binding.





Residence time (RT) indicates how long a ligand stays bound to its
receptor (Copeland et al., 2006;Hoffmann et al., 2015; Copeland, 2016)





The correlation between data sets was analyzed by Deming re-
gression, and the Pearson correlation coefficient (r2) was calculated
using GraphPad Prism 7.02.
Results
Pharmacological Characterization of Nluc-Tagged
hH3R and hH4R. To confirm that the N-terminally fused
Nluc does not affect hH3R and hH4R function, radioligand
saturation binding was measured on HEK293T cell homoge-
nates transiently expressing Nluc-hH3R or Nluc-hH4R and
compared with binding to their wild-type counterparts. The
radioligand [3H]NAMH displayed similar (P5 0.38, Student’s
t test) affinities for the wild-type hH3R (KD 5 1.37 6 0.3 nM,
Bmax 5 1.5 6 0.4 pmol/mg, n 5 5) and the Nluc-hH3R (KD 5
1.78 6 0.8 nM, Bmax 5 11 6 10 pmol/mg, n 5 7), indicating
that N-terminal fusion to Nluc does not significantly affect the
orthosteric hH3R ligand-binding site (Fig. 1A). Likewise,
saturation binding of [3H]histamine to wild-type hH4R and
Nluc-hH4R revealed similar (P 5 0.22, Student’s t test) KD
values of 4.4 6 0.6 nM (n 5 3) and 2.9 6 1.4 nM (n 5 3),
respectively, even though Nluc-hH4R expression was lower
(Bmax 5 5.6 6 1.4 pmol/mg and 1.3 6 0.4 pmol/mg for hH4R
and Nluc-hH4R, respectively) (Fig. 1B).
Stimulation of HEK293T cells transiently expressing Nluc-
hH3R orNluc-hH4Rwith histamine resulted in a concentration-
dependent inhibition of 1 mM forskolin-induced CRE reporter
gene activity with potency (pEC50) values of 8.66 0.1 and 8.36
0.3, respectively, confirming thatN-terminalNluc fusion to these
receptors did not affect their signaling capacity as comparedwith
wild-type hH3R (pEC50 5 8.76 0.1) and hH4R (pEC50 5 8.26
0.2) (data not shown). In contrast, the fluorescent ligand
FL-histamine (Supplemental Fig. 1) did not induce Nluc-hH3R
or Nluc-hH4R–mediated inhibition of forskolin-induced CRE
reporter gene activity. Clobenpropit acted as an antagonist
and full agonist at the Nluc-hH3R (a 5 0.0) and Nluc-hH4R
(pEC505 8.86 0.4,a5 1.06 0.1), respectively (Fig. 1, C andD),
although previously reported for wild-type hH3R as an inverse
agonist and hH4R agonist (Lim et al., 2005). Its fluorescent
derivative clo-BDY (structure not disclosed by manufacturer)
acted as an antagonist at Nluc-hH3R and full agonist (pEC50 5
8.06 0.1, a5 1.06 0.0) at Nluc-hH4R (Fig. 1, C andD). Indeed,
hH3R-mediated inhibition of forskolin-induced CRE reporter
gene activity in response to increasing concentrations of
histaminewas antagonized by 5mMFL-histamine or 1mMclo-
BDY, resulting in a parallel right shift of the histamine
concentration-response curve (Supplemental Fig. 2A). Sur-
prisingly, FL-histamine (10mM) did not affect hH4R-mediated
CRE reporter gene activity in response to increasing concen-
trations of histamine (Supplemental Fig. 2B), suggesting that
FL-histamine does not interact with the hH4R.














NanoBRET-Based Saturation and Competition Bind-
ing on Intact Cells Expressing Nluc-hH3R and Nluc-
hH4R. Binding of red fluorescent clo-BDY or green fluores-
cent FL-histamine to living intact HEK293T cells expressing
either Nluc-hH3R or Nluc-hH4Rwas quantified as NanoBRET
between the luminescentNlucdonor and the fluorescentBODIPY
acceptor moiety. Incubation of cells expressing either Nluc-hH3R
or Nluc-hH4R for 2 hours at 25°C with increasing concentrations
of clo-BDY resulted in a saturable increase in NanoBRET signals
under equilibrium conditions, resulting in KD values of 13 6
1.9 and 706 30 nM for Nluc-hH3R and Nluc-hH4R, respectively
(Fig. 2, A and C). Saturation binding of FL-histamine displayed
moderate affinityKD5 427687 nM for theNluc-hH3R (Fig. 2E).
Surprisingly, no specific binding could be observed on cells
expressing the Nluc-hH4R if tested up to a concentration of
10 mM (data not shown), which is in contrast to the previously
reportedFL-histamine binding to hH4R onmurine bonemarrow–
derived mast cells with a KD of 2.1 mM as measured by flow
cytometry (Mirzahosseini et al., 2015).
Coincubation of a single concentration of clo-BDY (50 nM) or
FL-histamine (1 mM) in combination with a selection of un-
labeled ligands and cells expressing either Nluc-hH3R or Nluc-
hH4R for 2 hours at 25°C resulted in a concentration-dependent
decrease in NanoBRET by histamine and clobenpropit, indicat-
ing that these unlabeled ligands compete with the fluorescent
ligand for binding to both the Nluc-hH3R and Nluc-hH4R (Fig. 2,
B,D, andF). In contrast, thehH3R-selective antagonist pitolisant
only competed with clo-BDY and FL-histamine for binding to
Nluc-hH3R (Fig. 2, B and F) but not for the binding of clo-BDY to
Nluc-hH4R (Fig. 2D). This selectivity profile toward H3R was
previously observed in radioligand-binding studies on wild-
type hH3R and hH4R (Ligneau et al., 2007). Oppositely, the
hH4R-selective antagonist JNJ7777120 only displaced clo-BDY
from Nluc-hH4R (Fig. 2D) but hardly from Nluc-hH3R (Fig. 2B),
which is in line with its previously reported 300-fold lower
affinity for the H3R compared with the H4R (Lim et al., 2005).
Binding affinities (pKi) of unlabeled ligands for Nluc-hH3R
and Nluc-hH4R were calculated from the NanoBRET-based
competition-binding assays using the Cheng-Prusoff equation
(Cheng and Prusoff, 1973) and subsequently compared with
pKi values that were derived from radioligand competition
binding towild-type hH3R or hH4R (Table 1). A clear difference is
observed between agonists and antagonists in the linear corre-
lation of their pKi values for the hH3R obtained in competition
with either clo-BDY or [3H]NAMH (Fig. 3A). Agonists consis-
tently displayed lower binding affinities in theNanoBRET-based
binding assay as compared with the radioligand-binding assay
with a correlation of r2 5 0.8556 (P 5 0.003). In contrast,
antagonists tended to display more comparable affinities for
hH3R and Nluc-hH3R in both assay formats with a correlation
of r2 5 0.8008 (P 5 0.015). A similar difference in agonist
affinities for the hH3R is observedwhen comparing FL-histamine
with [3H]NAMH competition-binding curves. Again, antag-
onists tended to display more comparable pKi values in both
NanoBRET- and radioligand-based assays (Supplemental
Table 1). Indeed, pKi values of unlabeled ligands obtained
with either “red” tracer clo-BDY or “green” tracer FL-histamine
in Nluc-hH3R competition-binding assays showed a high overall
linear correlation (r2 5 0.9794, P , 0.0001) (Fig. 3B).
The NanoBRET-based hH4R competition-binding assays on
intact cells yielded lower pKi values for all tested ligands as
compared with radioligand competition-binding assays on cell
homogenates (Table 1). Yet, a correlation was observed for the
pKi values of both agonists (r
2 0.7673,P5 0.004) and antagonists
(r2 0.9184, P 5 0.01) between the two hH4R-binding assay
formats (Fig. 3C).
Fig. 1. Pharmacological characterization of Nluc-fused hH3R and hH4R. (A) Specific binding of [
3H]NAMH to HEK293T cell homogenates expressing
wild-type (wt) hH3R orNluc-hH3R. (B) Specific binding of [
3H]histamine toHEK293T cell homogenates expressingwild-type hH4R orNluc-hH4R. Ligand-
induced Nluc-hH3R (C) and Nluc-hH4R (D) activation as measured by CRE-luc reporter gene assay in transiently cotransfected HEK293T cells.
Representative graphs of at least three experiments performed in triplicate are shown. RLU, relative luminescence units.














Binding Kinetics of Fluorescent Clo-BDY on Nluc-hH3R
Measured by NanoBRET. As both clo-BDY and FL-histamine
display similar binding affinities of unlabeled ligands in equilib-
rium competition binding, clo-BDY was selected as a fluorescent
ligand for real-time detection of ligand binding due to its
higher affinity and smaller spectral overlap with NanoLuc.
Real-time detection of NanoBRET upon the addition of three
concentrations (approximately 4, 8, and 16 KD) of clo-
BDY to intact HEK293T cells expressing Nluc-hH3R at 25°C
revealed monophasic association binding of clo-BDY to the
Nluc-hH3R with globally fitted kon and koff values of 2.0 6
1.4  105 M21×min21 and 0.048 6 0.02 min21, respectively
(Fig. 4A). The reciprocal of the koff value indicated that clo-
BDY has an RT of 23 6 8.0 minutes on the Nluc-hH3R.
Calculation of the equilibrium dissociation constant from
the ratio of koff to kon (KD 5 koff/kon) revealed a 39-fold lower
“kinetic” KD value (5 513 6 272 nM) of clo-BDY for Nluc-
hH3R as compared with its KD (5 13 6 1.9 nM) obtained
from the saturation binding curve at equilibrium (Fig. 2A).
Binding Kinetics of Unlabeled Ligands on Nluc-hH3R
Measured by NanoBRET. Real-time measurement of the
binding of clo-BDY (100 nM) to the Nluc-hH3R in the absence
and presence of unlabeled hH3R ligands allowed the determi-
nation of the binding rate constants of the latter by using the
Motulsky and Mahan method (Motulsky and Mahan, 1984). A
shallow initial overshoot followed by a lower clo-BDY “steady-
state” binding to Nluc-hH3R was observed in the presence of
10 nM (40Ki) unlabeled clobenpropit, which indicates slower
dissociation kinetics for unlabeled clobenpropit to the Nluc-
hH3R as compared with clo-BDY (Fig. 4B). In contrast, clo-
BDY binding to Nluc-hH3R gradually reached equilibrium in
the presence of 5011 nM (10 Ki) unlabeled histamine,
indicating that this endogenous hH3R agonist has faster
receptor-binding kinetics for the Nluc-hH3R in comparison
with clo-BDY (Fig. 4C). Indeed, unlabeled clobenpropit and
histamine had 1.8-fold lower and 1.9-fold higher koff values,
respectively, as compared with clo-BDY (Table 2), resulting
in a proportionally longer (44 6 21 minutes) and shorter
Fig. 2. NanoBRET equilibrium saturation binding of clo-BDY on Nluc-hH3R (A), Nluc-hH4R (C), and FL-histamine on Nluc-hH3R (E) transiently
expressed on intact HEK293T cells. NanoBRET competition binding of clo-BDY to the Nluc-hH3R (B) and Nluc-hH4R (D), and FL-histamine on Nluc-
hH3R (F) transiently expressed on intact HEK293T cells. Representative graphs of at least three experiments performed in triplicate are shown.














(126 3.8minutes) RT onNluc-hH3R than clo-BDY. The agonists
imetit andNAMHdisplayed faster binding kinetics as compared
with clo-BDY, with RT values of 18 6 12 and 18 6 7.4 minutes,
respectively (Table 2). The antagonist thioperamide displayed
comparably slow binding kinetics as unlabeled clobenpropit,
whereas antagonists A-331440 and [49-{3-([R,R]2,5-dimethyl-
pyrrolidin-1-yl)-propoxy}-biphenyl-4-yl]-morpholin-4-yl-methanone
(A-349821) bound the Nluc-hH3R with faster kinetics and RTs
of 206 14.6 and 176 6.7minutes, respectively (Table 2). In this
assay, the koff value (0.066 6 0.02 minute
21) of unlabeled
A-349821 on intact HEK293T cells was similar to the previously
observed dissociation rate constant for the dissociation of pre-
bound [3H]A-349821 from membranes of hH3R-expressing C6
cells (Witte et al., 2006).
The only currently marketed hH3R-targeting antagonist,
pitolisant (Wakix), bound the Nluc-hH3R with relatively fast
kinetics (kon 5 1.4 6 1.0  106 M21×min21 and koff 5 0.086 6
0.07 minute21), resulting in an RT of 176 10 minutes (Fig. 4D;
Table 3). Interestingly, considerable variation was observed in
the target residence time of five hH3R antagonists that have
been or are currently in clinical trials. The RT of bavisant
(Fig. 4E) and PF-03654746 was in the same range as pitolisant,
with RT values of 8.46 2.3 and 156 4.1 minutes, respectively
(Table 3). In contrast, considerably longer residence times for
binding to Nluc-hH3R were observed for GSK1004723 (59 6
83 minutes) and ABT-239 (75 6 52 minutes), resulting in an
initial overshoot of clo-BDY binding to Nluc-hH3R (Fig. 4F).
The “kinetic pKD” calculated from the observed kon and koff
values of the unlabeled ligands in the competitive association-
binding assay revealed a linear relationship (r2 5 0.7398, P5
0.0007) with the corresponding pKi values that were derived
from competition-binding curves under equilibrium condi-
tions using the same NanoBRET technology (Fig. 5A; Tables
2 and 3). However, the calculated kinetic pKD values were up
to 50-fold lower than the observed pKi (Fig. 5A). Interestingly,
ligand affinity (pKi) of unlabeled ligands was linearly corre-
lated (r2 5 0.7789, P 5 0.0003) to the log kon (Fig. 5B), but no
correlation (r2 5 0.067, P5 0.441) was found between pKi and
log koff values (Fig. 5C), suggesting that the on-rate of ligands
drives hH3R affinity (Sykes et al., 2009; Guo et al., 2016).
TABLE 1
Affinity of H3 and H4 ligands on the wild-type hH3R (wt-hH3R) and wt-hH4R using radioligand and Nluc-hH3R and Nluc-hH4R using NanoBRET-based
competition binding assays
Data represent the mean 6 S.D. of at least three experiments performed in triplicate.
Compound
Nluc-hH3R wt-hH3R Actiona Compound
Nluc-hH4R wt-hH4R Actiona
pKi vs. clo-BDY pKi vs. [
3H]NAMH pKi vs. clo-BDY pKi vs. [
3H]histamine
Histamine 6.3 6 0.2* 7.9 6 0.3 A Histamine 6.8 6 0.3* 7.9 6 0.2 A
NAMH 7.8 6 0.2* 8.8 6 0.1 A VUF8430 6.8 6 0.3* 7.5 6 0.1b A
Imetit 8.3 6 0.4* 9.7 6 0.4 A Imetit 7.4 6 0.1* 8.4 6 0.3 A
SAMH 6.4 6 0.4* 7.6 6 0.8 A VUF8328 7.6 6 0.2* 8.4 6 0.1 A
Immepip 8.5 6 0.5* 9.3 6 0.1 A VUF4656 7.5 6 0.1* 8.8 6 0.1b A
Dimaprit 5.9 6 0.3 6.1 6 0.2 A VUF5228 5.9 6 0.3* 7.3 6 0.2b A
VUF5524 6.6 6 0.2* 7.5 6 0.1 A 4-methylhistamine 6.4 6 0.2* 7.3 6 0.1b A
Clobenpropit 9.6 6 0.1 10.0 6 0.4 I Clobenpropit 7.4 6 0.3* 8.0 6 0.1 A
Thioperamide 7.3 6 0.3 7.2 6 0.2 I Thioperamide 7.2 6 0.4 7.5 6 0.2 I
Iodophenpropit 8.9 6 0.4 9.2 6 0.4 I Iodophenpropit 7.6 6 0.2* 8.2 6 0.3 I
A-331440 7.7 6 0.4* 8.6 6 0.1 I VUF6002 7.1 6 0.3 7.7 6 0.1b I
A-349821 9.7 6 0.6 9.7 6 0.0 I VUF10499 6.8 6 0.2* 7.3 6 0.1 I
Pitolisant 8.6 6 0.0* 8.0 6 0.2 I Pitolisant ,5 ND ND
JNJ7777120 ,5 5.3 6 0.1b ND JNJ7777120 7.9 6 0.2 8.2 6 0.1 I
A, agonist; I, antagonist/inverse agonist in CRE-luciferase reporter gene or guanosine 59-O-(3-[35S]thio)triphosphate ([35S]GTPgS) assay, ND, not determined; VUF10499,
6-chloro-N-(furan-3-ylmethyl)2-(4-methylpiperazin-1-yl)quinazolin-4-amine; VUF4656, 3-(1H-imidazol-4-yl)propyl (3,4-dichlorobenzyl)carbamimidothioate dihydrobromide; VUF5228,
3-(1H-imidazol-4-yl)propyl (E)-N-(4-chlorobenzyl)-N9-cyclohexylcarbamimidothioate dihydrobromide; VUF5524, 4-pentyl-1H-imidazole oxalate; VUF6002, 5-chloro-
2-((1-methylpiperidin-4-ylidene)methyl)-1H-benzo[d]imidazole; VUF8328, 3-(1H-imidazol-4-yl)propyl carbamimidothioate dihydrobromide; VUF8430, 2-guanidinoethyl carbamimidothioate
dihydrobromide.
aAction obtained from Lim et al. (2005), Bongers et al. (2007), and Nijmeijer et al. (2013b).
bpKi values obtained from Lim et al. (2005) and Nijmeijer et al. (2013); data are the mean 6 S.E.M.
*Significant differences in pKi values between the NanoBRET-based and radioligand binding assays (P , 0.05) as determined by Student’s t test.
Fig. 3. Correlation plots of equilibrium dissociation constants (pKi) of ligands for Nluc-hH3R (A and B) and Nluc-hH4R (C) as obtained by radioligand or
NanoBRET-based competition-binding assays. Correlation of radioligand- and NanoBRET-based pKi values as determined by clo-BDY as tracer (A and
C). (B) Correlation between pKi of ligands measured in a NanoBRET-based competition binding assay versus fluorescent clo-BDY or FL-histamine on
Nluc-hH3R. Deming linear regression was used for data fitting, and dotted line shows line of unity.














Plotting the logarithm of kon versus the koff values illus-
trates that ligands with the same affinity, as indicated by
the diagonal lines, can have considerably different kinetics
(Fig. 5D).
Duration of Functional hH3R Antagonism. Next, the
duration of H3R antagonism was functionally measured upon
induction of prebound antagonist dissociation by washout of
unbound ligand to evaluate the impact of the RT (5 1/koff)
derived from the NanoBRET competitive association assay.
To this end, the recovery rate of hH3R responsiveness to
histamine (1 mM) stimulation was measured in transiently
transfected HEK293T cells by using the cAMP-sensitive
BRET-based biosensor CAMYEL at 37°C. Overnight preincu-
bation with 1 mM hH3R antagonists pitolisant or ABT-239
(pKi values were 8.6 6 0.0 and 9.0 6 0.2, respectively, in
NanoBRET-based binding on intact cells) followed by a
washout of unbound antagonist resulted in a full recovery of
hH3R responsiveness for the short-RT (17minutes) antagonist
pitolisant within 1.5 hours. In contrast, the prebound long-RT
(75 minutes) antagonist ABT-239 showed a much-slower
recovery of hH3R responsiveness to histamine stimulation,
and 60% of hH3R-mediated signaling was still blocked 4.5 hours
after its dissociation was initiated (Fig. 6).
Discussion
The availability of fluorescent ligands in combination with
the recently engineered Nluc luciferase allows the develop-
ment of NanoBRET-based ligand-receptor-binding assays
(Stoddart et al., 2015, 2018a,b; Soave et al., 2016). Since
NanoBRET only occurs if the fluorescent ligand is bound to the
Nluc-tagged GPCR, this assay can be performed in a homoge-
neous format without additional washing steps to separate
unbound from bound fluorescent ligand and is, therefore, well
suited to detect real-time ligand binding to GPCRs that are
expressed on living cells. Quantification of binding parame-
ters of a ligand for its GPCR on living cells is functionally
more relevant as compared with measurements on membrane
preparations or cell homogenates, as used buffer and in-
tracellular interacting proteins can affect the latter assays
(Emami-Nemini et al., 2013; Vauquelin et al., 2015; Bosma
et al., 2017; Vanderheyden and Benachour, 2017; Stoddart
et al., 2018). Here, a NanoBRET-based binding assay for the
Nluc-hH3R and Nluc-hH4R on intact cells was developed
utilizing the commercially available fluorescent ligands clo-BDY
and FL-histamine.
As shown in this study, unlabeled agonists displayed higher
affinity for the hH3R in cell homogenates as determined by
Fig. 4. Real-time detection of clo-BDY binding to Nluc-hH3R by NanoBRET. (A) Association of three concentrations of clo-BDY. Competition association
assay of 100 nM clo-BDY in competition with clobenpropit (B), histamine (C), pitolisant (D), bavisant (E), and ABT-239 (F) on the Nluc-hH3R transiently
expressed on HEK293T cells at 25°C. Representative graphs of at least three experiments performed in triplicate are shown.
TABLE 2
Kinetic parameters of unlabeled ligands, determined by competition association assays of clo-BDY to
Nluc-hH3R
Data represent the mean 6 S.D. of at least three experiments performed in triplicate.
Compound kon (M
21×min21) koff (min
21) RT (min) Kinetic “pKD” pKi
a
Histamine 8.0 6 7.3  104 0.089 6 0.02 12 6 3.8 5.8 6 0.4 6.3 6 0.2
NAMH 1.6 6 0.3  105 0.062 6 0.02 18 6 7.4 6.6 6 0.4 7.8 6 0.2
Imetit 9.1 6 8.7  105 0.092 6 0.07 17 6 12 6.9 6 0.5 8.3 6 0.4
Clobenpropit 1.4 6 0.6  107 0.026 6 0.01 44 6 21 8.7 6 0.1 9.6 6 0.1
Thioperamide 1.6 6 2.0  106 0.026 6 0.01 41 6 12 7.5 6 0.4 7.3 6 0.3
A-331440 2.3 6 3.0  105 0.078 6 0.05 20 6 14 6.3 6 0.3 7.7 6 0.4
A-349821 1.6 6 1.1  107 0.066 6 0.02 17 6 6.7 8.3 6 0.4 9.7 6 0.6
apKi values as determined in NanoBRET displacement assay (Table 1).














[3H]NAMH displacement in comparison with the NanoBRET-
based binding assay on intact cells. Indeed, higher-affinity
agonist-bound GPCR ternary complexes can be formed in
membrane preparations or cell homogenates with their associ-
ated G protein in the absence of free guanine nucleotides, as
compared with the more-transient ternary complexes in intact
cells resulting in lower agonist-binding affinities (Witte et al.,
2006; Strange, 2008; Chabre et al., 2009; Emami-Nemini et al.,
2013). Interestingly, a similar difference in the affinity of unlabeled
agonists for the hH3R was observed in competition-binding
experiments on cell homogenates using agonist [3H]NAMH
versus antagonist [125I]iodophenpropit as radioligands (Bongers
et al., 2007). Comparison of pKi values of unlabeled ligands
derived from the NanoBRET-based competition binding using
the fluorescent antagonist clo-BDY with those obtained from
[125I]iodophenpropit displacement revealed similar binding
affinities in both assay formats (r2 0.9239, P, 0.0001) without
an obvious discrepancy between unlabeled H3R agonists and
H3R antagonists (Fig. 7). In contrast to the [
3H]NAMH-
binding assay, both NanoBRET-based clo-BDY and [125I]-
iodophenpropit competition binding assays are performed
in buffers containing near-physiologic (∼140 mM) NaCl
TABLE 3
Kinetic parameters of H3R drug candidates, determined by competition association assay with clo-BDY
on the Nluc-hH3R
Data represent the mean 6 S.D. of at least three experiments performed in triplicate.
Compound kon 6 S.D. (M
21×min21) koff 6 S.D. (min
21) RT (min) Kinetic “pKD” pKi
a
Pitolisant 1.4 6 1.0  106 0.086 6 0.07 17 6 10 7.2 6 0.3 8.6 6 0.0
Bavisant 7.0 6 4.8  105 0.13 6 0.04 8.4 6 2.3 6.7 6 0.3 8.6 6 0.4
GSK189254 1.3 6 1.8  107 0.024 6 0.01 44 6 11 8.4 6 0.7 9.6 6 0.3
GSK1004723 2.3 6 2.1  105 0.037 6 0.03 59 6 83 6.7 6 0.2 8.0 6 0.1
PF-03654746 4.4 6 1.2  106 0.073 6 0.02 15 6 4.1 7.8 6 0.1 9.3 6 0.4
ABT-239 9.2 6 5.4  105 0.017 6 0.01 75 6 52 7.7 6 0.1 9.0 6 0.5
apKi obtained from NanoBRET assay (Table 1).
Fig. 5. Comparison of the affinity (pKi) of unlabeled ligands for the Nluc-hH3R obtained from equilibrium NanoBRET assays with their association and
dissociation rate constants and kinetic “pKD” from real-time measurements (Table 2). Deming linear regression was used for data fitting of pKi versus
pKD (A), pKi versus log kon (B), and pKi versus log koff (C). Distribution of log kon versus log koff in relation to their kinetic “KD” as represented by diagonal
lines (D). Dotted line shows line of unity.














concentrations (Bongers et al., 2007). Allosteric binding of
sodium to GPCRs often reduces agonist affinity by stabilizing
inactive receptor conformations but may also differently affect
the binding of antagonists to the orthosteric binding site
(Clark and Hill, 1995; Schnell and Seifert, 2010; Katritch
et al., 2014; Wittmann et al., 2014; Newton et al., 2016;
Hishinuma et al., 2017; Schiffmann and Gimpl, 2018).
Nonetheless, most antagonists displayed affinities in the
NanoBRET assay that were comparable to the radioligand-
based competition-binding assay. Lower hH4R-binding affin-
ities for both agonist and antagonists were also observed in the
NanoBRET-based binding assay on intact cells as compared
with radioligand binding to cell homogenates, despite the fact
that both labeled clo-BDY and [3H]histamine are agonists on
the hH4R. Similar to the hH3R, the presence of allosteric
sodium in the NanoBRET buffer may reduce affinities of both
agonists and antagonists for the hH4R. In addition, compet-
itive binding experiments and the Cheng-Prusoff equation
assume reversible interaction between competing ligands and
receptor. However, bound fluorescent agonists may induce
receptor internalization during the course of a binding
experiment on intact cells, which may result in the observa-
tion of lower pKi values for unlabeled ligands as compared
with binding assays on cell homogenates (Cheng and Prusoff,
1973; Guo et al., 2010).
The NanoBRET-based binding assay can detect binding of a
fluorescent ligand to living cells expressing the Nluc-tagged
receptor of interest with a high resolution in time, which also
allows for the measurement of a full association-binding curve
from a single sample (Hansen et al., 2017; Stoddart et al.,
2018). Detection of the association binding of a fluorescent
probe in the presence of unlabeled ligands allows quantifica-
tion of the kinetic rate constants and KD (5 koff/kon) values
of the latter. Since binding rate constants are sensitive to
temperature, the ionic composition of buffer, and can be
different in living cells versus cell homogenates or membrane
preparations (Sykes et al., 2010; Vanderheyden and Benachour,
2017), one might anticipate that absolute rate constants of the
few ligands that were previously reported in radioligand-binding
studies might be different from those obtained using the current
NanoBRET binding assay on living cells. Indeed, the hH3R
antagonist GSK1004723 displayed 5-fold faster dissociation
kinetics in the NanoBRET binding assay compared to that
previously reported (Slack et al., 2011), despite the lower
temperature (25°C instead of 37°C) used in NanoBRET. In
contrast, association and dissociation binding of the antago-
nist [3H]A-349821 tomembranes expressing the hH3R revealed
a 220-fold higher kon value and similar koff value as compared
with the NanoBRET-based competition association assay
(Witte et al., 2006).
Although a linear correlation was observed between pKi
and kinetic pKD values of unlabeled hH3R ligands in the
NanoBRET-based binding assays, the kinetic pKD valueswere
consistently lower than the affinities that were obtained from
the equilibrium binding assay. Hence, the absolute values of
the determined binding rate constants in this competitive
association binding should not be overinterpreted. However,
evaluation of the functional recovery rate of hH3R responsive-
ness to histamine stimulation upon dissociation of prebound
long- and short-RT antagonists, under assay conditions compa-
rable to the NanoBRET-based binding assay, revealed that
obtained RT values are indeed very indicative of the duration
of hH3R antagonism of these antagonists.
Hitherto, only pitolisant (Wakix) is approved as an hH3R-
targeting antagonist to increase wakefulness and alertness
in patients suffering from narcolepsy. Pitolisant was found
to have a moderate RT (17 minutes) on the hH3R, which
consequently resulted in a relatively fast target recovery rate
(Fig. 6). From the hH3R antagonists that have been or are
currently in clinical trials, bavisant and PF-03654746
have an RT comparable to pitolisant, whereas ABT-239
and GSK1004723 show substantially longer RTs. Recently, a
new trial was initiatedwith bavisant to assess excessive daytime
sleepiness in Parkinson’s disease patients (NCT03194217). The
long-residence-time antagonist GSK1004723 displayed a lack of
in vivo efficacy, whereas ABT-239 failed to enter clinical trials
due to drug safety issues (Hancock, 2006; Daley-Yates et al.,
2012). Insomnia is frequently reported as a side effect of hH3R
antagonists in clinical trials, and hence long-RT ligands might
further enhance this adverse event (Wijtmans et al., 2007; Brioni
and Esbenshade, 2011; Sadek et al., 2016; Schwartzbach et al.,
2017). Moreover, it was proposed that different ligands can
address distinct hH3R-related disorders (Esbenshade et al.,
2006; Wijtmans et al., 2007; Sander et al., 2008). Therefore,
Fig. 6. Functional washout of 1mMpitolisant or ABT-239 from the hH3Rand
their ability to antagonize histamine-induced hH3R activation. Cells were
incubated overnight with either 1 mM pitolisant or ABT-239. Subsequently,
cells were washed and allowed to re-equilibrate for different time periods
before stimulationwithhistamineanddetection of cAMP levelusingCAMYEL
biosensor. Representative graph of three experiments performed in duplicate
is shown.
Fig. 7. Comparison of pKi of unlabeled ligands for the hH3R obtained
from equilibrium NanoBRET assays with affinities obtained with
[125I]iodophenpropit from Bongers et al. (2007). Deming linear regression
was used for data fitting. Dotted line shows line of unity.














it remains to be seen what influence ligand kinetics have on
the plethora of hH3R-related therapeutic indications.
In conclusion, the NanoBRET-based competition equilib-
rium binding assay is a valuable tool to determine the binding
parameters of unlabeled ligands for their receptors on living
cells at reasonably high throughput under experimental condi-
tions that better correspond to those used in functional assays,
as compared with the traditional radioligand-binding studies
on cell homogenates or isolated membranes.
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